Nurtec ODT (rimegepant) is a brand-name drug prescribed for treating and preventing migraine in adults. Nurtec ODT comes as a tablet that dissolves in your mouth. The dosage can vary depending on ...
The US Department of Justice announced Friday that Pfizer has agreed in New York federal court to pay $59.7 million to resolve allegations that one of its subsidiaries caused false Medicare claims by ...
The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...
Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary made improper payments to physicians to boost sales of its migraine drug ...
Medically reviewed by Lindsay Cook, PharmD Ubrelvy (ubrogepant) and Nurtec (rimegepant) are prescription medications approved ...
Read more: Celebrities Who Were Diagnosed With Rare Diseases Nurtec orally disintegrating tablet, or ODT, is the brand name ...
Pfizer will pay nearly $60 million to settle claims that its subsidiary Biohaven used illegal kickbacks to drive sales of its migraine medicine Nurtec ODT.
Michigan has joined the U.S. Department of Justice, 37 other states and Puerto Rico in settling kickback allegations against a Pfizer, Inc. subsidiary. Pfizer has agreed to ...
Sales of Nurtec ODT (rimegepant) – approved as an oral therapy for migraine prevention and acute treatment – reached $194 million in sales in the fourth quarter of 2022. It competes with other ...
Biohaven is accused of giving health care providers cash and lavish meals to get them to prescribe Nurtec ODT, a migraine medication.
Pfizer paid $11.6bn to buy Biohaven, largely on the financial performance of Nurtec ODT. The drug went on to generate global sales of $928m in sales in 2023. Known as Vydura in Europe, Nurtec ODT ...
Rimegepant 75mg; orally disintegrating tabs (ODT). Concomitant strong CYP3A4 inhibitors: Avoid use with Nurtec ODT. Concomitant moderate CYP3A4 inhibitors: Avoid another dose of Nurtec ODT within ...